Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma

Loading news article.

Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma | WAPE

Pasithea Therapeutics Amends Clinical Study Protocol For Phase 1/1b Trial Of PAS-004 In Neurofibromatosis Type 1 Patients With Symptomatic Inoperable, Incompletely Resected, Or Recurrent Plexiform Neurofibroma

Article summary

Related companies

Comments —